Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke
Standard
Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. / Fann, D Yang-Wei; Lee, S Y; Manzanero, S; Tang, S C; Gelderblom, M; Chunduri, P; Bernreuther, C; Glatzel, M; Cheng, Y L; Thundyil, J; Widiapradja, A; Lok, K Z; Foo, S L; Wang, Y C; Li, Y I; Drummond, G R; Basta, M; Magnus, T; Jo, D G; Mattson, M P; Sobey, C G; Arumugam, T V.
In: CELL DEATH DIS, Vol. 4, 01.01.2013, p. e790.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke
AU - Fann, D Yang-Wei
AU - Lee, S Y
AU - Manzanero, S
AU - Tang, S C
AU - Gelderblom, M
AU - Chunduri, P
AU - Bernreuther, C
AU - Glatzel, M
AU - Cheng, Y L
AU - Thundyil, J
AU - Widiapradja, A
AU - Lok, K Z
AU - Foo, S L
AU - Wang, Y C
AU - Li, Y I
AU - Drummond, G R
AU - Basta, M
AU - Magnus, T
AU - Jo, D G
AU - Mattson, M P
AU - Sobey, C G
AU - Arumugam, T V
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Multi-protein complexes called inflammasomes have recently been identified and shown to contribute to cell death in tissue injury. Intravenous immunoglobulin (IVIg) is an FDA-approved therapeutic modality used for various inflammatory diseases. The objective of this study is to investigate dynamic responses of the NLRP1 and NLRP3 inflammasomes in stroke and to determine whether the NLRP1 and NLRP3 inflammasomes can be targeted with IVIg for therapeutic intervention. Primary cortical neurons were subjected to glucose deprivation (GD), oxygen-glucose deprivation (OGD) or simulated ischemia-reperfusion (I/R). Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion. Neurological assessment was performed, brain tissue damage was quantified, and NLRP1 and NLRP3 inflammasome protein levels were evaluated. NLRP1 and NLRP3 inflammasome components were also analyzed in postmortem brain tissue samples from stroke patients. Ischemia-like conditions increased the levels of NLRP1 and NLRP3 inflammasome proteins, and IL-1β and IL-18, in primary cortical neurons. Similarly, levels of NLRP1 and NLRP3 inflammasome proteins, IL-1β and IL-18 were elevated in ipsilateral brain tissues of cerebral I/R mice and stroke patients. Caspase-1 inhibitor treatment protected cultured cortical neurons and brain cells in vivo in experimental stroke models. IVIg treatment protected neurons in experimental stroke models by a mechanism involving suppression of NLRP1 and NLRP3 inflammasome activity. Our findings provide evidence that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke. We also identified NLRP1 and NLRP3 inflammasome inhibition as a novel mechanism by which IVIg can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that target inflammasome assembly and activity.
AB - Multi-protein complexes called inflammasomes have recently been identified and shown to contribute to cell death in tissue injury. Intravenous immunoglobulin (IVIg) is an FDA-approved therapeutic modality used for various inflammatory diseases. The objective of this study is to investigate dynamic responses of the NLRP1 and NLRP3 inflammasomes in stroke and to determine whether the NLRP1 and NLRP3 inflammasomes can be targeted with IVIg for therapeutic intervention. Primary cortical neurons were subjected to glucose deprivation (GD), oxygen-glucose deprivation (OGD) or simulated ischemia-reperfusion (I/R). Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion. Neurological assessment was performed, brain tissue damage was quantified, and NLRP1 and NLRP3 inflammasome protein levels were evaluated. NLRP1 and NLRP3 inflammasome components were also analyzed in postmortem brain tissue samples from stroke patients. Ischemia-like conditions increased the levels of NLRP1 and NLRP3 inflammasome proteins, and IL-1β and IL-18, in primary cortical neurons. Similarly, levels of NLRP1 and NLRP3 inflammasome proteins, IL-1β and IL-18 were elevated in ipsilateral brain tissues of cerebral I/R mice and stroke patients. Caspase-1 inhibitor treatment protected cultured cortical neurons and brain cells in vivo in experimental stroke models. IVIg treatment protected neurons in experimental stroke models by a mechanism involving suppression of NLRP1 and NLRP3 inflammasome activity. Our findings provide evidence that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke. We also identified NLRP1 and NLRP3 inflammasome inhibition as a novel mechanism by which IVIg can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that target inflammasome assembly and activity.
KW - Adaptor Proteins, Signal Transducing
KW - Animals
KW - Apoptosis Regulatory Proteins
KW - Brain Ischemia
KW - Carrier Proteins
KW - Caspase 1
KW - Caspase Inhibitors
KW - Cell Death
KW - Cells, Cultured
KW - Cerebral Cortex
KW - Cytoprotection
KW - Disease Models, Animal
KW - Humans
KW - Immunoglobulins, Intravenous
KW - Inflammasomes
KW - Interleukin-18
KW - Interleukin-1beta
KW - Mice
KW - Mice, Inbred C57BL
KW - Neurons
KW - Stroke
KW - Treatment Outcome
U2 - 10.1038/cddis.2013.326
DO - 10.1038/cddis.2013.326
M3 - SCORING: Journal article
C2 - 24008734
VL - 4
SP - e790
JO - CELL DEATH DIS
JF - CELL DEATH DIS
SN - 2041-4889
ER -